High rates of HBsAg seroconversion in HBeAg-positive chronic hepatitis B patients responding to interferon: A long-term follow-up study

Moucari, Rami; Korevaar, Anneke; Lada, Olivier; Martinot–Peignoux, Michelle; Boyer, Nathalie; Mackiewicz, Vincent; Dauvergne, Agnès; Cardoso, Ana Carolina; Asselah, Tarik; Nicolas–Chanoine, Marie–Hélène; Vidaud, Michel; Valla, Dominique; Bédossa, Pierre; Marcellin, Patrick

doi:10.1016/j.jhep.2009.01.016

Cited by 171 publications

(165 citation statements)

References 36 publications

Supporting

Mentioning

156

Contrasting

Order By: Relevance

“…This is supported by natural history studies showing increased survival, lower rates of hepatic decompensation and reduction in the frequency of HCC in patients who cleared HBsAg (30)(31)(32)(33)(34)(35). In carriers with cirrhosis at HBsAg seroclearance and with no evidence of viral superinfection, liver function can improve or remain stable and hepatic decompensation rarely occurs.…”

Section: Hbsag: Clinical Relevancementioning

confidence: 78%

Quantification of hepatitis B surface antigen: a new concept for the management of chronic hepatitis B

Moucari

Marcellin

2011

Liver International

Self Cite

View full text Add to dashboard Cite

HBsAg is a very important clinical test that might not only indicate active hepatitis B virus (HBV) infection but might also be used to predict clinical and treatment outcome. Clearance of HBsAg in patients with chronic HBV infection is associated with a much better clinical outcome, although surveillance for early detection of hepatocellular carcinoma (HCC) should continue. HBV DNA quantification is currently used for selecting candidates for therapy, monitoring response to therapy and detecting the emergence of drug resistance. Assays for HBsAg quantification are less expensive than HBV DNA and fully automated with a high throughput capacity. HBsAg titering may be a useful tool to manage patients with chronic HBV, to more clearly define which patients may, and more importantly, may not, benefit from treatment. Baseline and on-treatment HBsAg quantification may help to refine future treatment algorithms for both immune-modulator therapy and nucleos(t)ide analogues. Both HBV markers provide complementary information on the status of HBV infection. However, the relevance of serum HBsAg levels and its use as a reliable replacement for both covalently closed circular DNA and HBV DNA remain unclear.

show abstract

Section: Hbsag: Clinical Relevancementioning

confidence: 78%

Quantification of hepatitis B surface antigen: a new concept for the management of chronic hepatitis B

Moucari

Marcellin

2011

Liver International

Self Cite

View full text Add to dashboard Cite

show abstract

“…Studies conducted in Europe and the USA have reported that the late disappearance of HBsAg occurred in 12%-65% of the patients, within five years of HBeAg loss, but it was rarely observed in among Asian patients. 8,[31][32][33][34][35] Among patients who received a one-year treatment with PEG-IFN, 9%-11% lost HBsAg three years after the end of treatment. 24,30 Therefore, predictors for disappearance of HBsAg during treatment are more important than those for seroconversion, but a longer-term follow-up is necessary for their assessment.…”

Section: Sustained Response Versus Maintained Responsementioning

confidence: 99%

Response predictors to treatment with pegylated interferon in chronic hepatitis B

Ferreira

Tenore

2010

Braz J Infect Dis

View full text Add to dashboard Cite

The clinical and epidemiological importance of chronic B hepatitis is currently unquestionable as a cause of end-stage liver disease and hepatocellular carcinoma. Recently, predictors of treatment response of this disease have been studied, both before and during the course of medication. Therapy stopping rules have been proposed, which may be useful in patients presenting poor treatment tolerance. This review discusses the treatment response predictors usefulness, with emphasis on ALT, quantitative HBsAg and HBeAg, quantitative HBV-DNA and HBV genotyp

show abstract

“…HBsAg clearance is the closest to cure outcome as one can expect to achieve in hepatitis B. Support for this comes from natural history studies demonstrating increased length of survival, lower rates of hepatic decompensation, and reduction in the frequency of hepato cellular carcinoma in patients with cirrhosis who clear HBsAg [10][11][12]. Despite the added clinical importance of HBsAg clearance, this event has not been included as a primary end point in treatment trials because of the low frequency of its occurrence.…”

Section: Qualitative Hbsagmentioning

confidence: 99%

Chronic hepatitis B: back to the future with HBsAg

Moucari

Lada

Marcellin³

2009

Expert Review of Anti-infective Therapy

Self Cite

View full text Add to dashboard Cite

High rates of HBsAg seroconversion in HBeAg-positive chronic hepatitis B patients responding to interferon: A long-term follow-up study

Cited by 171 publications

References 36 publications

Quantification of hepatitis B surface antigen: a new concept for the management of chronic hepatitis B

Quantification of hepatitis B surface antigen: a new concept for the management of chronic hepatitis B

Response predictors to treatment with pegylated interferon in chronic hepatitis B

Chronic hepatitis B: back to the future with HBsAg

Contact Info

Product

Resources

About